Member Info for bootnk19222

As this is now in free fall wonder what the placing price could be.25-.2?

Who the hell is buying at this price and why?

😂😂😂 integrity, GDR get their spin techniques from Starmer

There’s one thing guaranteed in all this is that Gino is an unprofessional bulls..ter at best. At worst who knows what underhand dealings he has up his sleeve. The NHS and MPs , especially Labour, are no less corrupt, reminds me of Boris the bell..d and his ‘we will make the UK the centre of world diagnostics’ whilst all the time selling out to the Chinese. The NHS won’t deal with a public company so guess where this is going. No doubt there’ll be a Labour MP at the head of this taking back handlers

Well that’s not a good sign. Must be an employee out there had the heads up

Now that we are where I predicted let’s have a look at the leaked information detrimental.

The leak suggests that centralised labs can’t scale this year due to budget/funding limitations. This means hospitals wanting to comply with NICE guidance now may look for a locally fundable, rapid alternative — which is exactly what Genedrive’s device offers.

• The “repository of tools” and CERSI guidance could still support local adoption, meaning trusts could roll out GDR’s test without waiting for national lab commissioning.

3. The risk factor

• Any slowdown in overall adoption of CYP2C19 testing (lab or POC) could delay peak sales forecasts.

• If NHS trusts interpret this as “wait until national funding” rather than “use local funding and POC kits,” near-term uptake could be muted unless GDR’s sales team actively pushes the “do it now” narrative.

• GDR’s biggest challenge will be making sure decision-makers understand that the NICE delay doesn’t apply to them if they go POC.

4. Bottom line

• Lab-based approach: Dented for 2025; funding not secured this FY.

• POC approach (Genedrive): Potentially more attractive now, as it bypasses the stalled funding pipeline — but GDR must be proactive in marketing that advantage.

• Investor takeaway: This isn’t the bad news it looks like at first glance. It could actually be a competitive advantage moment if GDR pivots the messaging right now.

But let’s see what the company has to say

I’ve been saying .8 for months now. Ready and waiting

Can’t raise below 1.5 , how many more times??

Absolute balloon as usual

.8 is my bet, been saying it for months.

0.8 on the way 👍

You’re in fantasy world again carrot, up the meds before you get sectioned

Once 1.2 goes .8 will be my punt guess

GDR must be the only company on AIM with a multitude of distributers that don’t actually distribute anything. Classic. Meanwhile the pigs are still gorging themselves at the trough of ever decreasing hard working share holders money. Scum. Can’t think why Ia ones thriving uk alternative market is now on its arse

You’ve just totally made that up

Hang on, I’ll just ring NICE for you , see if they’ll give me insider information 🙄

There are some people on these boards that will actually believe this bull.

You all witnessed the corruption with the emergency use Chinese LFTs , totally destroying the UK diagnostic industry. There are still UK LFTs that are stuck in red tape. This is no different. Whilst the product is still in the test stage the NHS can avoid liability thus saving short term funds, regardless of long term savings. By the time these two tests get through the red tape it will be another governments liability problem .

Interesting volume this morning, wonder what’s going on ?

Think everyone knows carrot is an absolute balloon so no need to explain